Chihiro Nozaki

Chihiro Nozaki

Auto-generated profile, based on publicly available information

Chihiro Nozaki

Waseda University

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2007 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JKJunzo Kamei
Junzo Kamei
SHShun-Suke Hayashi
Shun-Suke Hayashi
YTYoshiki Takahashi
Yoshiki Takahashi
CNChihiro Nozaki
Chihiro Nozaki

22 August 2024 in Life Sciences
Verified
Journal Article
Open access
HHHaruka Hosoki
Haruka Hosoki
TAToru Asahi
Toru Asahi
CNChihiro Nozaki
Chihiro Nozaki
It is known that the cannabinoid type 2 (CB2) receptor has an anti-inflammatory role. Therefore, animals without CB2 receptors show enhanced inflammation and pain in the model of chronic pain, e.g., neuropathic pain. We previously proposed the upregulated leptin signaling at the peripheral nerve as one of the underlying molecular mechanisms of pain exacerbation in nerve-injured CB2 knockouts, as they displayed robust upregulation of leptin receptors and leptin signaling in the peripheral nerve. Due to these past results, we hypothesized that CB2 receptor deficiency might also modify the peripheral neuroinflammation led by chronic exposure to a high-fat diet (HFD). Interestingly, CB2 knockout animals showed significant resistance to HFD-induced neuroinflammation. Namely, 5-week feeding of HFD induced substantial hypersensitivity in WT animals, while tactile sensitivity of HFD-fed CB2 knockouts remained intact. HFD-fed WT animals also displayed the robust upregulation of chemokine CXCR4 expression with increased macrophage infiltration, which was never observed in HFD-fed CB2 knockout mice. Moreover, 5-week HFD exposure led significant increase of CD11b+Ly6G-Ly6Chigh cells and a decrease of CD11b+Ly6G+Ly6Clow cells in the spleen of WT animals, which was also not found in either HFD-fed CB2 knockouts or standard diet-fed WT and CB2 animals. Together with past reports, these results suggest that CB2 receptors might have a double-sided regulatory role in the context of inflammation development or, more widely, immune system regulation. We propose that CB2 signaling is not always anti-inflammatory and could take a pro-inflammatory role depending on the cause of the inflammation.

9 September 2024 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
KIKaede Ito
Kaede Ito
HHHaruka Hosoki
Haruka Hosoki
YKYuya Kasai
Yuya Kasai
HSHiroyuki Sasaki
Hiroyuki Sasaki
AHAtsushi Haraguchi
Atsushi Haraguchi
CNChihiro Nozaki
Chihiro Nozaki

3 April 2025 in Neuropharmacology
Verified
Journal Article
Closed access
KMKazuaki Mori
Kazuaki Mori
ATAkinobu Togo
Akinobu Togo
KYKota Yamashita
Kota Yamashita
SSShigeo Sakuragi
Shigeo Sakuragi
HBHiroko Bannai
Hiroko Bannai
KKKosuke Kataoka
Kosuke Kataoka

2 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
HHHaruka Hosoki
Haruka Hosoki
TAToru Asahi
Toru Asahi
CNChihiro Nozaki
Chihiro Nozaki
It is known that cannabinoid type 2 (CB2) receptor has anti-inflammatory role, therefore animals without CB2 receptors show enhanced inflammation and pain in the model of chronic pain e.g. neuropathic pain. We previously proposed the upregulated leptin signaling at the peripheral nerve as one of the underlying molecular mechanisms of pain exacerbation in nerve-injured CB2 knockouts, as they displayed robust upregulation of leptin receptors and leptin signaling in peripheral nerve. Due to these past results we hypothesized that CB2 receptor deficiency might also modify the peripheral neuroinflammation lead by chronic exposure to high fat diet (HFD). Interestingly, CB2 knockout animals showed the significant resistance to the HFD-induced neuroinflammation. Namely, 5-week feeding of HFD induced substantial hypersensitivity in WT animals, while tactile sensitivity of HFD-fed CB2 knockouts remained intact. HFD-fed WT animals also displayed the robust upregulation of chemokine CXCR4 expression with increased macrophage infiltration, which was never observed in HFD-fed CB2 knockout mice. Moreover, 5-week HFD-exposure lead significant increase of CD11b + Ly6G - Ly6C high cells and decrease of CD11b + Ly6G + Ly6C low cells in the spleen of WT animals, which was also not found in either HFD-fed CB2 knockouts or standard diet-fed WT and CB2 animals. Together with past report, these results suggest that CB2 receptors might have the double-sided regulatory role in context of the inflammation development, or more widely, immune system regulation. We propose that CB2 signaling is not always anti-inflammatory and could take pro-inflammatory role depending on the cause of the inflammation.

14 October 2026
Verified
Preprint
Open access
PDF file
AKAya Kuroda
Aya Kuroda
CPChenyu Pan
Chenyu Pan
LNLyie Nitta
Lyie Nitta
CNChihiro Nozaki
Chihiro Nozaki
Background: Cannabidiol (CBD) products are sold in many forms for many purposes, but it is largely unknown which characteristics of real-world use relate to how users evaluate their experience. Methods: We analyzed an anonymous web-based survey of 377 CBD product users in Japan. We evaluated perceived-effect (0–5) and satisfaction (0–6) scores using main regression models of use frequency adjusted for age, sex, and body mass index. Separate supplementary models examined estimated daily CBD amount and other-cannabinoid co-use, purposes of use, or specific CBD amount-reporting status. Results: Use frequency was positively associated with perceived effects (B = 0.148, 95% CI 0.091 to 0.205) and satisfaction (B = 0.113, 95% CI 0.049 to 0.177; both p < 0.001). Estimated daily amount showed no clear association with either outcome after adjustment, whereas participants who reported specific milligram information had higher scores on both (B = 0.543, p < 0.001 and B = 0.559, p = 0.002). Amount-reporting status was associated with product form (tincture 48.5% vs 30.8%; smoking or inhalation 58.5% vs 75.7%; both FDR-adjusted p = 0.009), whereas no statistically significant group differences were found for age, sex, body mass index, use frequency, or sleep timing. Purposes of use and sleep-timing indicators showed no clear associations with the outcomes. Conclusions: Subjective evaluation of CBD use was more consistently related to how often CBD was used and whether a specific milligram amount was reported than to how much was reportedly taken, and amount-reporting status was related to product form. Specific CBD amount-reporting status may be a useful complementary dimension for characterizing real-world CBD use.